Sam Fazeli

I mean, if you had X percent, what was most of it pneumonitis versus ILD?

How should we think about that?

And what would it mean for this patient population that is expected to live a long time?

So DDO5, which was the trial that you've referred to already, was an adjuvant trial, i.e.

patients were getting whatever neoadjuvant therapy the physician was giving them or none.

I'm assuming they all had some kind of neoadjuvant therapy, but you can, again, detail on that.

And then they got their surgery and then post-surgery,

If they had residual disease, i.e.

they were not PCR, they got inherited to 14 cycles plus, right?

So if you want to just tell us a little bit about what you saw in that trial again, in that setting, I think you mentioned the 53% improvement.

Okay.

So one of the things that, of course, a lot of the issues with several cancers is metastasis to the brain

Here, it wasn't immediately clear whether you had a meaningful, or at least the impact on brain mets was not clear.

Do you think we can have sufficient evidence in later follow-ups to assess a CNS prevention benefit in DBO5?

Okay, so last questions here.

If you have been a patient who has been treated with Enherto in the new adjuvant setting and you did not get a major pathologic response, so you were positive still,

Do you believe that you can move on to the DBO5 regime afterwards?

Of course, these are questions that are really relevant to our modeling for DBO9 and DBO3 too.

But let's just consider this question first.

Is four cycles enough from what you know about in HER2 to give you resistance?